Understanding and avoiding immortal-time bias in gastrointestinal observational research

American Journal of Gastroenterology

Volumn 110, Issue 12, 2015, Pages 1647-1650

  Targownik, Laura E ^a,b   Suissa, Samy ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL ERROR; ARTICLE; CLINICAL PRACTICE; CONSUMER; DIAGNOSIS; DISEASE COURSE; FOLLOW UP; GASTROENTEROLOGY; HUMAN; IMMORTAL PERSON TIME BIAS; INCIDENCE; MEDICAL LITERATURE; MEDICAL RESEARCH; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SURVIVAL; DRUG APPROVAL; ECONOMICS; INFLAMMATORY BOWEL DISEASES; METHODOLOGY; PROCEDURES; STATISTICAL BIAS; SURVIVAL ANALYSIS; TIME FACTOR; TRENDS;

GASTROINTESTINAL AGENT;

BIAS (EPIDEMIOLOGY); DRUG APPROVAL; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; OBSERVATIONAL STUDIES AS TOPIC; PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84951569622     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.210     Document Type: Article

References (15)

1. Cartwright N, Munro E. The limitations of randomized controlled trials in predicting effectiveness. J Eval Clin Pract 2010; 16: 260-6
2. Sanson-Fisher RW, Bonevski B, Green LW, et al. Limitations of the randomized controlled trial in evaluating population-based health interventions. Am J Prev Med 2007; 33: 155-61
3. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. JAMA 2007; 297: 1233-40
4. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92
5. Alvarez-Requejo A, Porta M. Pharmacoepidemiology in practice. Current status and future trends. Drug Saf 1995; 13: 1-7
6. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-9
7. Rothman KJ, Suissa S. Exclusion of immortal person-Time. Pharmacoepidemiol Drug Saf 2008; 17: 1036
8. Fidder H, Schnitzler F, Ferrante M, et al. Long-Term safety of infl iximab for the treatment of infl ammatory bowel disease: A single-centre cohort study. Gut 2009; 58: 501-8
9. Targownik LE. Immortal time bias and infl iximab-related mortality and malignancy incidence. Gut 2010; 59: 416
10. Lewis JD. Immortal time bias in estimates of mortality among infl iximabtreated patients with Crohn's disease. Gut 2010; 59: 1586-7
11. Magro F, Rodrigues-Pinto E, Coelho R, et al. Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol 2014; 109: 1026-36
12. Targownik L. The importance of accounting for immortal time bias in pharmacoepidemiologic analyses. Am J Gastroenterol 2015; 110: 349
13. Magro F, Rodrigues-Pinto E, Coelho R, et al. Response to Targownik. Am J Gastroenterol 2015; 110: 349-51.
14. Picco MF, Zubiaurre I, Adluni M, et al. Immunomodulators are associated with a lower risk of fi rst surgery among patients with non-penetrating nonstricturing Crohn's disease. Am J Gastroenterol 2009; 104: 2754-9
15. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportionalhazards regression model. Annu Rev Public Health 1999; 20: 145-57